These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


265 related items for PubMed ID: 31743134

  • 1. A case of pelvic giant cell tumor of bone, complete remission with denosumab: long duration of response.
    Bilgetekin I, Mammadkhanli O, Basal FB, Kandemir O, Canbay S, Oksuzoglu B.
    Anticancer Drugs; 2020 Jun; 31(5):533-535. PubMed ID: 31743134
    [Abstract] [Full Text] [Related]

  • 2. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
    Reddy K, Ramirez L, Kukreja K, Venkatramani R.
    J Pediatr Hematol Oncol; 2021 Mar 01; 43(2):e215-e218. PubMed ID: 31714440
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Denosumab, a Potential Alternative to the Surgical Treatment of Distal Radius Giant Cell Tumor of Bone: Case Report.
    Park MJ, Ganjoo KN, Ladd AL.
    J Hand Surg Am; 2015 Aug 01; 40(8):1620-4. PubMed ID: 25935517
    [Abstract] [Full Text] [Related]

  • 8. Giant cell tumour of bone in the denosumab era.
    van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H.
    Eur J Cancer; 2017 May 01; 77():75-83. PubMed ID: 28365529
    [Abstract] [Full Text] [Related]

  • 9. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
    Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, Roberts ZJ, Bach BA.
    Ann Surg Oncol; 2015 Sep 01; 22(9):2860-8. PubMed ID: 26033180
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
    Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, Leopardi MP, Syed I, Sankhala KK, Parthasarathy P, Mendanha WE, Pierini M, Paioli A, Chawla SP.
    Eur J Cancer; 2017 May 01; 76():118-124. PubMed ID: 28324746
    [Abstract] [Full Text] [Related]

  • 15. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
    Palmerini E, Seeger LL, Gambarotti M, Righi A, Reichardt P, Bukata S, Blay JY, Dai T, Jandial D, Picci P.
    BMC Cancer; 2021 Jan 22; 21(1):89. PubMed ID: 33482769
    [Abstract] [Full Text] [Related]

  • 16. Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy.
    Matcuk GR, Patel DB, Schein AJ, White EA, Menendez LR.
    Skeletal Radiol; 2015 Jul 22; 44(7):1027-31. PubMed ID: 25712768
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunohistochemical Characterization of Giant Cell Tumor of Bone Treated With Denosumab: Support for Osteoblastic Differentiation.
    Kerr DA, Brcic I, Diaz-Perez JA, Shih A, Wilky BA, Pretell-Mazzini J, Subhawong TK, Nielsen GP, Rosenberg AE.
    Am J Surg Pathol; 2021 Jan 22; 45(1):93-100. PubMed ID: 32773532
    [Abstract] [Full Text] [Related]

  • 19. Current management of giant-cell tumor of bone in the denosumab era.
    Nagano A, Urakawa H, Tanaka K, Ozaki T.
    Jpn J Clin Oncol; 2022 May 05; 52(5):411-416. PubMed ID: 35199172
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 14.